Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
186
-
Total 13F shares, excl. options
-
108M
-
Shares change
-
+9.51M
-
Total reported value, excl. options
-
$286M
-
Value change
-
+$32M
-
Put/Call ratio
-
1.2
-
Number of buys
-
101
-
Number of sells
-
-56
-
Price
-
$2.65
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2025
217 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 186 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 108M shares
of 207M outstanding shares and own 52.06% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.8M shares), VANGUARD GROUP INC (12.1M shares), Two Seas Capital LP (9.75M shares), WASATCH ADVISORS LP (7.06M shares), PenderFund Capital Management Ltd. (6.68M shares), GEODE CAPITAL MANAGEMENT, LLC (4.75M shares), STATE STREET CORP (4.48M shares), MORGAN STANLEY (4.06M shares), Nuveen, LLC (3.71M shares), and AIGH Capital Management LLC (3M shares).
This table shows the top 186 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.